Drug Pricing Controls Detrimental: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw, CMD of Biocon, tells NDTV that the NPPA's decision to add more drugs under price control will have a detrimental impact on the industry and the pharmaceutical sector has been completely overlooked in this Budget.

Related Videos